Micro Emerging Archived

Lilly's Retevmo cuts recurrence risk in RET+ early-stage NSCLC

New narrative with limited coverage — still forming.

Score
0.2
Velocity
▲ 0.0
Articles
1
Sources
1

Sentiment Timeline

Event Timeline

May 31, 2026
Eli Lilly's Retevmo Phase 3 LIBRETTO-432 Cuts Recurrence Risk 83% In RET+ … Neutral

Related Articles

Eli Lilly's Retevmo Phase 3 LIBRETTO-432 Cuts Recurrence Risk 83% In RET+ Early-Stage NSCLC

Nasdaq · May 31, 2026
Mixed

Timeline

Last UpdatedMay 31, 2026